2. Immunology/Inflammation
  3. PGE synthase
  4. HPGDS inhibitor 3

HPGDS inhibitor 3 是一种具有口服活性且高效的外周限制性造血前列腺素 D 合成酶 (H-PGDS) 抑制剂，IC50 为 9.4 nM，EC50 为 42 nM。HPGDS inhibitor 3 具有良好的选择性，在小鼠、大鼠和犬体内的药动学参数良好，且无中枢神经系统毒性。HPGDS inhibitor 3 具有抗炎活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

HPGDS inhibitor 3 Chemical Structure

HPGDS inhibitor 3 Chemical Structure

CAS No. : 2255311-93-2

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

HPGDS inhibitor 3 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

HPGDS inhibitor 3 is an orally active and highly potent peripherally restricted hematopoietic prostaglandin D synthase (H-PGDS) inhibitor with IC50 value of 9.4 nM and EC50 of 42 nM, respectively. HPGDS inhibitor 3 exhibits good selectivity, good pharmacokinetic parameters in mouse, rat, and dog, and no CNS toxicity. HPGDS inhibitor 3 has anti-inflammatory activity[1].

IC50 & Target

IC50: 9.4 nM (H-PGDS)[1]
EC50: 42 nM (H-PGDS)[1]
体内研究
(In Vivo)

HPGDS inhibitor 3 (compound 1y) (1-3 mg/kg; PO and IV; single) has a lower IV clearance, similar steady state volume of distribution, longer terminal half-life, and high oral bioavailability, as well as very low brain exposures in mouse, rat and dog[1].
HPGDS inhibitor 3 (0.003-1 mg/kg; PO; single) attenuates PGD2 release to baseline levels in a dose-dependent manner; also inhibits LPS-induced PGD2 increase in plasma and skeletal muscle in a dose-dependent manner[1].
HPGDS inhibitor 3 (0.003-1 mg/kg; PO; single) [1].
HPGDS inhibitor 3 (1, 3, and 10 mg/kg; PO; q.d., for 16 days) significantly enhances functional recovery of injured limbs, and hastens the time to full functional recovery of injured limb muscles[1].
HPGDS inhibitor 3 (10, 30 and 100 mg/kg; PO; once daily, for 7 days or 4 days) exhibits well tolerated at 30 mg/kg/day in rat but not tolerated at 100 mg/kg/day; shows well tolerated at 30 mg/kg/day in dogs but not tolerated at 75 mg/kg/day[1].
Pharmacokinetic Parameters of HPGDS inhibitor 3 in mice, rats and dogs[1].

Mouse
IV, 1 mg/kg
PO, 3 mg/kg		 Rat
IV, 0.4 mg/kg
PO, 2.4 mg/kg		 Dog
IV, 0.5 mg/kg
PO, 1 mg/kg
T1/2 (h) 2.9 5.1 6.2
CL (mL/min/kg) 9.0 4.5 1.9
Vss (L/kg) 1.6 1.6 1.0
F (%) 71 100 92
Brain:blood ratio 0.06

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male C57BL/6J mice (murine mast cell degranulation model of inflammation)[1]
Dosage: 0.003, 0.01, 0.03, 0.1, 0.3 and 1.0 mg/kg
Administration: PO; single (anesthetized 1 hour later, intraperitoneally injected with 0.2 mL PBS or 48/80 (0.75 mg/mL))
Result: Attenuated PGD2 release to baseline levels in a dose-dependent manner with an ED50 of 0.009 mg/kg (blood EC50 = 3.4 nM) in this acute inflammation model.
Animal Model: Male C57BL6/N mice (12 weeks, n=6)[1]
Dosage: 0.003, 0.01, 0.03, 0.1, 0.3 and 1.0 mg/kg
Administration: PO; single (intraperitoneally injection of PBS or 20 ng/kg LPS 1 hour later)
Result: Inhibited LPS-induced PGD2 increase in plasma and skeletal muscle in a dose-dependent manner.
Animal Model: Male C57Bl/6 mice (10-12 weeks, n=7-8; chronic eccentric contraction-induced muscle injury models)[1]
Dosage: 1, 3, and 10 mg/kg
Administration: PO; q.d., for 16 days
Result: Significantly enhanced functional recovery of injured limbs, and significantly hastened the time to full functional recovery of injured limb muscles, with maximal efficacy observed at ≥ 10 mg/kg q.d..
Animal Model: Mdx mouse (6-8 mouths, duchenne muscular dystrophy model)[1]
Dosage: 0.1, 0.3, 1, 3, and 10 mg/kg
Administration: PO; q.d., for 43 days
Result: Significantly improved functional recovery (~90% to 100% restoration), following eccentric contraction-induced muscle injury in mdx mice.
Animal Model: Male Wistar Han rat and dog[1]
Dosage: 10, 30 and 100 mg/kg for rat; 10, 30, and 75 mg/kg for dog
Administration: PO; once daily; for 7 days (rat) or for 4 days (dog)
Result: In rat, the AUC values at 10, 30, and 100 mg/kg/day were 120, 410, and 820 µg•hr/mL, respectively; respective Cmax values were 8.7, 24, and 57 μg/mL. In dog, it showed well tolerated at dose levels up to 30 mg/kg/day with no abnormal microscopic findings; but exhibited discoloration in the small intestine and esophagus (female) at 75 mg/kg/day.
Animal Model: Mice, rats, dongs[1]
Dosage: 1 mg/kg IV and 3 mg/kg p.o in mice, 0.4 mg/kg IV and 2.4 mg/kg PO in rat, 0.5 mg/kg IV and 1 mg/kg PO in dog
Administration: IV and PO; single (Pharmacokinetics Analysis)
Result: Had a lower IV clearance, similar steady state volume of distribution, longer terminal half-life, and high oral bioavailability, as well as very low brain exposures in mouse, rat and dog.
分子量

353.46

Formula

C21H27N3O2
CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

HPGDS inhibitor 3 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

HPGDS inhibitor 32255311-93-2HPGDS inhibitor3HPGDS inhibitor-3PGE synthaseProstaglandin E synthaseOrally activitySelectivityPharmacokineticAnti-inflammatoryInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
HPGDS inhibitor 3
目录号：
HY-146662
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z